MACROFed raises rates for first time since 2023, defying TrumpSep 16, 2026
MIRAMIRA Pharmaceuticals 2026 annual vote: 63.06% quorum, all proposals approvedSep 16, 2026
FIBKFirst Interstate BancSystem locks in Jeff Lee's COO pact with 2x change-in-control severanceSep 16, 2026
MACROTen-year Treasury yield falls as Fed lifts overnight rate 25 basis pointsSep 16, 2026
CRYPTOHouse panel advances first federal crypto tax framework as Senate's Clarity Act stumblesSep 16, 2026
UBERAave founder sees Uber-style growth path for DeFi as Clarity Act stalls in SenateSep 16, 2026
REGULATORYKeenan Allen faces two DUI charges after 0.224 breathalyzer readingSep 16, 2026
DEALSXenetic Biosciences all-stock deal would give Santersus AG shareholders 85% of combined companySep 16, 2026
MACROFed raises rates for first time since 2023, defying TrumpSep 16, 2026
MIRAMIRA Pharmaceuticals 2026 annual vote: 63.06% quorum, all proposals approvedSep 16, 2026
FIBKFirst Interstate BancSystem locks in Jeff Lee's COO pact with 2x change-in-control severanceSep 16, 2026
MACROTen-year Treasury yield falls as Fed lifts overnight rate 25 basis pointsSep 16, 2026
CRYPTOHouse panel advances first federal crypto tax framework as Senate's Clarity Act stumblesSep 16, 2026
UBERAave founder sees Uber-style growth path for DeFi as Clarity Act stalls in SenateSep 16, 2026
REGULATORYKeenan Allen faces two DUI charges after 0.224 breathalyzer readingSep 16, 2026
DEALSXenetic Biosciences all-stock deal would give Santersus AG shareholders 85% of combined companySep 16, 2026

MIRA Pharmaceuticals 2026 annual vote: 63.06% quorum, all proposals approved

26,499,076 shares of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) common stock were present or represented by proxy at the company's 2026 Annual Meeting of Stockholders on September 11, 2026, representing 63.06% of the 42,022,087 shares…

By Kwame Asante·Sep 16, 2026·2 min read·regulatory·MIRA

Key takeaways

  • MIRA Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 11, 2026, with 26,499,076 shares (63.06% of 42,022,087 outstanding) present or represented by proxy.
  • All three proposals on the ballot passed, including the election of directors, auditor ratification, and an adjournment authorization.
  • All five director nominees—Erez Aminov, Matthew Pratt Whalen, Matthew Del Giudice, Denil Nanji Shekhat, and Edward MacPherson—were re-elected to the board.
  • Salberg & Company, P.A. was ratified as MIRA's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 25,950,852 votes for and no broker non-votes.
  • Proposal 3 authorizing an adjournment to gather additional proxies passed 24,897,741 to 1,205,307, but the contingency was not triggered.

26,499,076 shares of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) common stock were present or represented by proxy at the company's 2026 Annual Meeting of Stockholders on September 11, 2026, representing 63.06% of the 42,022,087 shares outstanding as of the July 21, 2026 record date. All three proposals on the ballot passed.

Director vote

Five directors were returned to the board: Erez Aminov, Matthew Pratt Whalen, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson, each to serve until the next annual meeting or until their successors are duly elected and qualified. Broker non-votes held uniform at 5,713,034 across all five nominees. The Aminov line reconciles the count: 20,559,502 for, plus 226,540 withheld, plus 5,713,034 broker non-votes sums to 26,499,076.

Nominee Votes for Broker non-votes
Erez Aminov 20,559,502 5,713,034
Matthew Pratt Whalen 20,560,180 5,713,034
Matthew Del Giudice, M.D. 20,558,412 5,713,034
Denil Nanji Shekhat, M.D. 20,138,206 5,713,034
Edward MacPherson 20,435,527 5,713,034

Shekhat drew the lowest "for" count of the five at 20,138,206, roughly 422,000 votes below Whalen's 20,560,180. Each of the 42,022,087 outstanding shares carried one vote per matter at the meeting.

Auditor ratification and contingency

Salberg & Company, P.A. was ratified as independent registered public accounting firm for fiscal year ending December 31, 2026. The vote: 25,950,852 for, 158,064 against, 390,160 abstentions, no broker non-votes. Those three figures sum to 26,499,076, reconciling to the full quorum. The against share was 158,064 of 26,499,076 total present, under 0.6%.

Proposal 3 authorized an adjournment to gather additional proxies if needed. It cleared 24,897,741 to 1,205,307, with 396,028 abstentions. The contingency was not triggered.

The proposals were described in MIRA's definitive proxy statement filed with the SEC on July 28, 2026. MIRA, an emerging growth company incorporated in Florida, trades on the Nasdaq Capital Market with principal offices at 1200 Brickell Avenue, Suite 1950, Miami. Chief Executive Officer Erez Aminov signed the September 16, 2026 8-K.

Related reading

Share
Source: sec.gov
© 2026 NewsMeter

Frequently asked

When was MIRA Pharmaceuticals' 2026 Annual Meeting held and what was the quorum?

The meeting was held on September 11, 2026, with 26,499,076 shares present or represented by proxy, representing 63.06% of the 42,022,087 shares outstanding as of the July 21, 2026 record date.

Which director received the lowest number of votes?

Denil Nanji Shekhat, M.D. drew the lowest 'for' count of the five nominees at 20,138,206 votes, roughly 422,000 votes below Whalen's 20,560,180.

Who was ratified as MIRA's auditor for fiscal 2026?

Salberg & Company, P.A. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, by a vote of 25,950,852 for, 158,064 against, and 390,160 abstentions.

What was Proposal 3 and was it used?

Proposal 3 authorized an adjournment of the meeting to gather additional proxies if needed; it passed 24,897,741 to 1,205,307, but the contingency was not triggered.

Who signed the 8-K reporting the vote results?

Chief Executive Officer Erez Aminov signed the September 16, 2026 8-K.